14 results about "No synthase" patented technology

The present invention relates to compositions and methods for treating and / or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP-PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected / stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and / or cell-based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling.

The invention relates to modulation of oral health by nitric oxide synthase pathways. Pharmaceutical compositions and methods for treating or preventing diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulating the nitric oxide synthase pathway are provided, as well as animal models and drug screening methods. This modulation may be accomplished by administering tetrahydrobiopterin (BH4), or a prodrug and / or salt thereof. Treatment and prevention of xerostomia may also have downstream effects of preventing periodontitis, decayed teeth, parotid gland enlargement, lip inflammation and dehiscence (cheilitis), tongue and buccal mucosa inflammation or ulcer, oral candidiasis, salivary gland infection (salivary adenitis), halitosis, and oral mucosa dehiscence and dehiscence.

The invention discloses an application of nitric oxide synthase neurons in an island leaf cortex II layer in preparation of a medicine for treating osteoporosis, and systematically reveals a nerve stress induced bone metabolism imbalance mechanism by constructing a chronic heterologous pressure stress mouse model and combining an enzyme-linked immunosorbent assay and a high-resolution micro-CT (Computed Tomography) technology; the method comprises the following steps: accurately positioning specific nerve connection between nNOS neurons of an island leaf cortex II layer and bone tissues for the first time by adopting a reverse cross-polysynaptic virus tracing technology, and determining that the region is a key central target point regulated and controlled by a brain-bone axis; the activity of target neurons is specifically intervened through a chemical genetics technology, it is proved that activation can induce the phenotype of osteoporosis, and pathologic indexes are remarkably improved through inhibition.

The invention relates to the technical field of microbial infection treatment and molecular biology, and provides a method for inhibiting formation of a staphylococcus aureus biofilm, which is realized by inhibiting nitrosation modification of MgrA protein in staphylococcus aureus so as to inhibit formation of the biofilm. The inhibitor is nitric oxide synthase and is used for inhibiting nitrosation modification of the MgrA protein; the nitrosation modification for inhibiting the MgrA protein is realized by applying a nitric oxide synthase (NOS) inhibitor; the invention reveals that the staphylococcus aureus endogenous nitric oxide can promote the formation of a biofilm by modifying and regulating the 12th cysteine of the protein MgrA for the first time; based on the target spot, research proves that the MgrA modification level can be effectively reduced and the removal of the biofilm can be enhanced through multiple means such as gene mutation, NOS inhibitor or combination of the NOS inhibitor and antibiotics, and a new strategy and a potential drug development approach are provided for preventing and treating staphylococcus aureus intractable biofilm infection.

The present invention relates to a composition and a method capable of predicting sulfonylurea dependence in diabetic patients by identifying the variants of: rs777077261(C>A) of KCNB2(Potassium Voltage-Gated Channel Subfamily B Member 2); rs202112906(C>T) of GHSR(Growth hormone secretagogue receptor); rs28944173(T>C) of NOS2(Nitric oxide synthase 2); rs3792268(C>A) of CAPN10(Calpain 10); rs199670165(C>A), rs17848945(C>T), rs755372392(G>A), rs200840955(G>A), rs200842352(C>A) or rs45489599(C>T) of FASN(Fatty acid synthase); rs185358392(G>A), rs769120237(G>A), rs201884071(G>A) or rs766766661(C>T) of KCNH6(Potassium Voltage-Gated Channel Subfamily H Member 6); rs14847401(G>A), rs37551700(G>A) or rs774656238(A>G) of DIS3L2(DIS3 like 3'-5' exoribonuclease 2); or rs74315349(G>A) or rs150546920(C>G) of NR0B2(Nuclear Receptor Subfamily 0 Group B Member 2).

This invention discloses the application of Dendrobium huoshanense protocorms in anti-fatigue and kidney-tonifying and aphrodisiac effects. Combining Dendrobium huoshanense protocorms with Cistanche deserticola, American ginseng, Rubus idaeus, Cornus officinalis, and Lycium barbarum significantly enhances the anti-fatigue and kidney-tonifying and aphrodisiac effects of the formula. Compared with Cistanche deserticola alone, adding Dendrobium huoshanense protocorms significantly prolongs the exhaustive swimming time in mice, reduces serum urea nitrogen and lactic acid levels, increases liver glycogen content, and increases muscle glycogen content. Compared with Cistanche deserticola alone, adding Dendrobium huoshanense protocorms significantly increases serum superoxide dismutase activity, reduces serum malondialdehyde content, increases serum testosterone content, increases penile nitric oxide synthase activity, and increases penile nitric oxide and cyclic guanosine monophosphate content in penile tissue.

Microparticles that contain miRNA that controls the production of nitric oxide and are an agent for promoting the production of nitric oxide are new microparticles that enable controlling the expression of a protein and / or a gene related to erectile dysfunction; a preventive drug or a therapeutic drug for erectile dysfunction; a method for improving erectile dysfunction; it is preferable that the microparticles be exosomes; and it is preferable that the microparticles of the present disclosure contain miRNA targeting a gene concerning the expression of nitric oxide synthase as the miRNA that controls the production of nitric oxide, and be an agent for promoting the expression of nitric oxide synthase.

The invention discloses application of a nitric oxide synthase inhibitor in preparation of a tumor treatment medicine, and belongs to the technical field of biological medicines. Experiments prove that the feasibility of injecting the NOS inhibitor NOS1-IN-1 into a tumor to target the NOS / CREB / BNNF pathway so as to inhibit mouse breast cancer innervation is realized. The development of the mouse breast cancer is successfully inhibited by applying NOS1-IN-1 local injection. The application provides favorable support evidence for the development of a strategy for inhibiting tumors by blocking innervation, especially in the aspect of safety, side effects caused by traditional tumor denervation are reduced, a new view angle for inhibiting tumor progression is provided, and the application has important scientific research value and application potential.

The embodiment of the invention discloses a modeling method of a periodontitis and preeclampsia combined model, which comprises the following steps of: performing first-stage periodontitis modeling on an experimental mouse through continuous orthodontic ligation for 10 days, and performing continuous annular ligation for 10 days on the basis to perform second-stage periodontitis modeling on the experimental mouse, when the expression level of the inflammation gene of the gingival tissue of the experimental mouse is obviously increased, the periodontitis model of the experimental mouse is successfully established. The method comprises the following steps of: performing preeclampsia modeling on the basis of experimental mice of which periodontitis models are successfully established, randomly dividing pregnant female experimental mice into a model group and a control group, and injecting a nitric oxide synthase inhibition solution into the experimental mice in the model group, when the tail artery systolic pressure of the experimental mice in the model group is increased by at least 20mmHg compared with that of the control group and is continuously increased until the end of pregnancy, the periodontitis and preeclampsia combined model of the experimental mice is successfully established, and the model has important academic value and clinical significance for reducing the occurrence rate of complications in the gestation period and improving maternal and fetal prognosis.

The invention discloses a pyrimidine derivative or a pharmaceutically acceptable salt thereof. The general formula of the pyrimidine derivative is shown as a formula I; wherein n is 1 or 2, m is 0 or 1, and l is 1 or 2; x1 is selected from a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a halogen C1-C6 alkyl group, and a C3-C6 cycloalkyl group; in the formula, R3 is selected from H, halogen, nitryl, cyano, halogen C1-C6 alkyl and C1-C6 alkoxy; y1 and Y2 are independently selected from C, N, O and S; r1 and R2 are independently selected from H, halogen, nitryl, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogen C1-C6 alkyl, C1-C6 alkoxy, carbamoyl and ester group. The compound can inhibit the inducible nitric oxide synthase and is used for preparing a medicine for inhibiting the inducible nitric oxide synthase.

The anti-inflammatory composition promotes proliferation of macrophage and suppresses inflammation caused by inflammatory cytokine and / or NO synthase, and promotes proliferation of human fibroblast or human epidermal keratinocyte and promotes synthesis of hyaluronic acid in epidermis and dermis. To provide a skin-beautifying and promoting composition which keeps the tension of the skin, strengthens the bonding force of the skin, improves the barrier function of the skin, enhances the strength and water-retaining function of the skin surface, or promotes the anti-aging of the skin, to provide a hair-growing composition which promotes the proliferation of human epidermal keratinocyte cells, improves the strength of the skin surface, and promotes hair growth, and to provide cosmetic compositions thereof.SOLUTION: The composition comprises a high-pressure treated product of a mixture of sturgeon eggs and 1, 3-butylene glycol.SELECTED DRAWING: Figure 3

The application discloses a one-oxygen-based fusion enzyme color developing agent and application. The color developing agent comprises a one-oxygen-based fusion enzyme, and the fusion enzyme is combined by a nitric oxide synthase, a flavoprotein and a flavoprotein reductase in sequence and two by two through a connecting peptide. The fusion enzyme provided by the application has high enzyme activity, can catalyze a large amount of one-oxygen, and can effectively combine myoglobin in meat products to generate nitroso-myoglobin, effectively improve the red color of the meat products, and obtain a color developing effect equivalent to that of sodium nitrite, thereby providing a very practically applicable solution for replacing the sodium nitrite color developing of the meat products and improving the safety of the meat products.

A color former based on a fusion enzyme producing nitric oxide and use thereof are provided. The color former includes the fusion enzyme producing nitric oxide. The fusion enzyme is formed by sequentially combining nitric oxide synthase, flavoprotein and flavoprotein reductase pairwise via linker peptides. The fusion enzyme provided by the present disclosure has relatively high enzyme activity, can catalytically produce a large amount of nitric oxide, and can effectively bind to myoglobin in meat products to produce nitrosylmyoglobin, thereby effectively enhancing the red color of the meat products to obtain a color forming effect equivalent to that of sodium nitrite, and providing a highly practical solution for nitrite color forming replacement of meat products and improvement of meat product safety.

The invention discloses a method for modifying human umbilical cord mesenchymal stem cells through nitric oxide synthase genes and application of the human umbilical cord mesenchymal stem cells. According to the method, the mesenchymal stem cells are modified by constructing a recombinant retroviral vector carrying a specific nitric oxide synthase gene (SEQ ID NO.1) and transfecting UCMSCs, so that the modified mesenchymal stem cells have remarkable effects in the aspects of repairing the penile erection function, improving the testosterone level and the like, and can be used for treating diabetic penile erection dysfunction.